This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2017 Oct 28;390(10106):1929-1930.

doi: 10.1016/S0140-6736(17)32418-2. Epub 2017 Sep 12.

PARP inhibitors for targeted treatment in ovarian cancer

Affiliations

Affiliation

¹ Women's Cancers, Lifespan Cancer Institute, Medical Oncology, Rhode Island Hospital, Medicine, Alpert Medical School of Brown University, Providence, RI 02903, USA. Electronic address: don.dizon@Lifespan.org.

PMID: 28916370
DOI: 10.1016/S0140-6736(17)32418-2

Review

PARP inhibitors for targeted treatment in ovarian cancer

Don S Dizon. Lancet. 2017.

. 2017 Oct 28;390(10106):1929-1930.

doi: 10.1016/S0140-6736(17)32418-2. Epub 2017 Sep 12.

Author

Affiliation

¹ Women's Cancers, Lifespan Cancer Institute, Medical Oncology, Rhode Island Hospital, Medicine, Alpert Medical School of Brown University, Providence, RI 02903, USA. Electronic address: don.dizon@Lifespan.org.

PMID: 28916370
DOI: 10.1016/S0140-6736(17)32418-2

No abstract available

PubMed Disclaimer

Similar articles

Olaparib, a new hope for ovarian cancer.
Samoon Z, Jabbar AA. Samoon Z, et al. Indian J Cancer. 2020 Jul-Sep;57(3):346-347. doi: 10.4103/ijc.IJC_1_19. Indian J Cancer. 2020. PMID: 32675438 No abstract available.
Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
Miller RE, Crusz SM, Ledermann JA. Miller RE, et al. Future Oncol. 2019 Jun;15(16):1845-1853. doi: 10.2217/fon-2019-0057. Epub 2019 Apr 30. Future Oncol. 2019. PMID: 31037967
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Miller RE, Ledermann JA. Miller RE, et al. Clin Adv Hematol Oncol. 2016 Aug;14(8):619-27. Clin Adv Hematol Oncol. 2016. PMID: 27487106 Review.
Olaparib for the treatment of epithelial ovarian cancer.
McLachlan J, Banerjee S. McLachlan J, et al. Expert Opin Pharmacother. 2016;17(7):995-1003. doi: 10.1517/14656566.2016.1165205. Epub 2016 Apr 4. Expert Opin Pharmacother. 2016. PMID: 26967466 Review.
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Gunderson CC, Moore KN. Gunderson CC, et al. Future Oncol. 2015;11(5):747-57. doi: 10.2217/fon.14.313. Future Oncol. 2015. PMID: 25757679 Review.

See all similar articles

Cited by

Paris saponin VII reverses resistance to PARP inhibitors by regulating ovarian cancer tumor angiogenesis and glycolysis through the RORα/ECM1/VEGFR2 signaling axis.
Wang M, Yuan C, Wu Z, Xu M, Chen Z, Yao J, Que Z, Tian J, Leung EL, Wang Z. Wang M, et al. Int J Biol Sci. 2024 Apr 15;20(7):2454-2475. doi: 10.7150/ijbs.91861. eCollection 2024. Int J Biol Sci. 2024. PMID: 38725854 Free PMC article.
Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres.
Fennell D, Griffiths D, Eminton Z, Morgan-Fox A, Hill K, Ewings S, Stuart C, Johnson L, Mallard K, Nye M, Darlison L, Dulloo S, Cave J, Luo JL, Taylor P, Spicer J, Poile C, Bzura A, Griffiths G. Fennell D, et al. BMJ Open. 2023 Nov 22;13(11):e073120. doi: 10.1136/bmjopen-2023-073120. BMJ Open. 2023. PMID: 37993149 Free PMC article.
Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies.
Wei Y, Erfani S, Schweer D, de Gouvea R, Qadir J, Shi J, Cheng K, Wu D, Craven R, Wu Y, Olivier T, Baldwin LA, Zhou B, Zhou Y, Zhao W, Yang BB, Ueland FR, Yang XH. Wei Y, et al. Mol Ther Oncolytics. 2023 Feb 19;28:293-306. doi: 10.1016/j.omto.2023.02.006. eCollection 2023 Mar 16. Mol Ther Oncolytics. 2023. PMID: 36911068 Free PMC article. Review.
Anlotinib Suppressed Ovarian Cancer Progression via Inducing G2/M Phase Arrest and Apoptosis.
Zhu Y, Wang X, Chen Z, Zhou L, Di X, Fan P, He Z. Zhu Y, et al. J Clin Med. 2022 Dec 25;12(1):162. doi: 10.3390/jcm12010162. J Clin Med. 2022. PMID: 36614964 Free PMC article.
Olaparib, a PARP-1 inhibitor, protects retinal cells from ocular hypertension-associated oxidative damage.
Yang Y, Wu J, Lu W, Dai Y, Zhang Y, Sun X. Yang Y, et al. Front Cell Dev Biol. 2022 Aug 26;10:925835. doi: 10.3389/fcell.2022.925835. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36092711 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- Genetic Alliance
- MedlinePlus Health Information

-